KR100500351B1 - 택소이드, 이의 제조방법 및 이를 함유하는 약학 조성물 - Google Patents

택소이드, 이의 제조방법 및 이를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR100500351B1
KR100500351B1 KR10-1998-0704792A KR19980704792A KR100500351B1 KR 100500351 B1 KR100500351 B1 KR 100500351B1 KR 19980704792 A KR19980704792 A KR 19980704792A KR 100500351 B1 KR100500351 B1 KR 100500351B1
Authority
KR
South Korea
Prior art keywords
carbon atoms
radical
radicals
formula
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1998-0704792A
Other languages
English (en)
Korean (ko)
Other versions
KR19990076680A (ko
Inventor
헤르베 부차르
알랭 코메르송
Original Assignee
아방티 파르마 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아방티 파르마 소시에테 아노님 filed Critical 아방티 파르마 소시에테 아노님
Publication of KR19990076680A publication Critical patent/KR19990076680A/ko
Application granted granted Critical
Publication of KR100500351B1 publication Critical patent/KR100500351B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR10-1998-0704792A 1995-12-22 1996-12-19 택소이드, 이의 제조방법 및 이를 함유하는 약학 조성물 Expired - Fee Related KR100500351B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/15,379 1995-12-22
FR9515379A FR2742751B1 (fr) 1995-12-22 1995-12-22 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR1996/002031 WO1997023473A1 (fr) 1995-12-22 1996-12-19 Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
KR19990076680A KR19990076680A (ko) 1999-10-15
KR100500351B1 true KR100500351B1 (ko) 2005-12-21

Family

ID=9485871

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0704792A Expired - Fee Related KR100500351B1 (ko) 1995-12-22 1996-12-19 택소이드, 이의 제조방법 및 이를 함유하는 약학 조성물

Country Status (40)

Country Link
US (1) US5728849A (enExample)
EP (1) EP0876362B1 (enExample)
JP (1) JP3953106B2 (enExample)
KR (1) KR100500351B1 (enExample)
CN (1) CN1103766C (enExample)
AR (1) AR005197A1 (enExample)
AT (1) ATE250593T1 (enExample)
AU (1) AU712597B2 (enExample)
BG (1) BG63204B1 (enExample)
BR (1) BR9612135A (enExample)
CA (1) CA2238884C (enExample)
CO (1) CO4520184A1 (enExample)
CZ (1) CZ294972B6 (enExample)
DE (1) DE69630145T2 (enExample)
DK (1) DK0876362T3 (enExample)
DZ (1) DZ2149A1 (enExample)
EA (1) EA001533B1 (enExample)
ES (1) ES2202490T3 (enExample)
FR (1) FR2742751B1 (enExample)
HU (1) HU225032B1 (enExample)
IL (1) IL124994A (enExample)
IN (4) IN186768B (enExample)
MA (1) MA26412A1 (enExample)
MX (1) MX9804688A (enExample)
MY (1) MY113934A (enExample)
NO (1) NO317358B1 (enExample)
NZ (1) NZ324337A (enExample)
OA (1) OA10700A (enExample)
PE (1) PE25198A1 (enExample)
PL (1) PL189311B1 (enExample)
PT (1) PT876362E (enExample)
RO (1) RO116194B1 (enExample)
SK (1) SK282835B6 (enExample)
TN (1) TNSN96169A1 (enExample)
TR (1) TR199801179T2 (enExample)
TW (1) TW371659B (enExample)
UA (1) UA48205C2 (enExample)
UY (1) UY24386A1 (enExample)
WO (1) WO1997023473A1 (enExample)
ZA (1) ZA9610737B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
IL145636A0 (en) 2000-02-02 2002-06-30 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2526278A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
FR3010839B1 (fr) * 2013-09-17 2017-04-21 Schneider Electric Ind Sas Dispositif de raccordement electrique d'au moins un conducteur dans une borne appartenant a un appareil electrique
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017724C1 (ru) * 1990-07-12 1994-08-15 Дзе Юниверсити оф Канзас Способ получения производных таксола
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
MX9307777A (es) * 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives

Also Published As

Publication number Publication date
NZ324337A (en) 2000-03-27
CA2238884C (fr) 2007-02-06
IN188469B (enExample) 2002-09-28
DZ2149A1 (fr) 2002-10-23
IN186768B (enExample) 2001-11-03
NO982580D0 (no) 1998-06-05
HUP9904046A1 (hu) 2001-04-28
KR19990076680A (ko) 1999-10-15
DK0876362T3 (da) 2004-02-02
EP0876362B1 (fr) 2003-09-24
CN1205697A (zh) 1999-01-20
EA001533B1 (ru) 2001-04-23
ZA9610737B (en) 1997-06-27
JP2000502671A (ja) 2000-03-07
MX9804688A (es) 1998-10-31
PT876362E (pt) 2004-02-27
AU1180997A (en) 1997-07-17
DE69630145T2 (de) 2004-07-15
WO1997023473A1 (fr) 1997-07-03
NO317358B1 (no) 2004-10-18
HK1017895A1 (en) 1999-12-03
ATE250593T1 (de) 2003-10-15
BG102569A (en) 1999-04-30
JP3953106B2 (ja) 2007-08-08
ES2202490T3 (es) 2004-04-01
SK282835B6 (sk) 2002-12-03
UY24386A1 (es) 2001-08-27
EP0876362A1 (fr) 1998-11-11
SK85398A3 (en) 1998-11-04
MA26412A1 (fr) 2004-12-20
EA199800588A1 (ru) 1998-12-24
CZ196198A3 (cs) 1998-09-16
CN1103766C (zh) 2003-03-26
CO4520184A1 (es) 1997-10-15
BG63204B1 (bg) 2001-06-29
HU225032B1 (en) 2006-05-29
MY113934A (en) 2002-06-29
IL124994A (en) 2000-12-06
BR9612135A (pt) 1999-07-13
TR199801179T2 (xx) 1998-10-21
AR005197A1 (es) 1999-04-14
CA2238884A1 (fr) 1997-07-03
CZ294972B6 (cs) 2005-04-13
US5728849A (en) 1998-03-17
FR2742751A1 (fr) 1997-06-27
TNSN96169A1 (fr) 2005-03-15
PL327405A1 (en) 1998-12-07
TW371659B (en) 1999-10-11
AU712597B2 (en) 1999-11-11
PL189311B1 (pl) 2005-07-29
PE25198A1 (es) 1998-05-10
IN188470B (enExample) 2002-09-28
FR2742751B1 (fr) 1998-01-30
RO116194B1 (ro) 2000-11-30
IL124994A0 (en) 1999-01-26
HUP9904046A3 (en) 2001-08-28
DE69630145D1 (de) 2003-10-30
IN188680B (enExample) 2002-10-26
OA10700A (fr) 2002-11-27
NO982580L (no) 1998-06-05
UA48205C2 (uk) 2002-08-15

Similar Documents

Publication Publication Date Title
KR100500351B1 (ko) 택소이드, 이의 제조방법 및 이를 함유하는 약학 조성물
JP3790826B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
US5847170A (en) Taxoids, their preparation and pharmaceutical compositions containing them
JP4308905B2 (ja) 新規なタキソイド、その製造及びそれを含有する製薬学的組成物
AU715228B2 (en) Taxoids, preparation thereof and pharmaceutical compositions containing same
AU703918B2 (en) New taxoids, their preparation and pharmaceutical compositions containing same
US6372780B2 (en) Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5840931A (en) Taxoids, their preparation and pharmaceutical compositions containing them
JPH10500979A (ja) 新規タキソイド類、その製造およびそれらを含む製薬学的組成物
JP3782447B2 (ja) 新規タキソイド類、その製造およびそれらを含む製薬学的組成物
US5968931A (en) Taxoids, preparation thereof and pharmaceutical compositions containing same
JPH10500981A (ja) 新規のタキソイド類、それらの製造、およびそれらを含む製薬学的組成物
HK1017895B (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20120611

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130701

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130701

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000